RT Journal Article
SR Electronic
T1 Improved diagnosis of COVID-19 vaccine-associated myocarditis with cardiac scarring identified by cardiac magnetic resonance imaging
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.03.20.24304640
DO 10.1101/2024.03.20.24304640
A1 Warren, Josephine
A1 Cheng, Daryl
A1 Crawford, Nigel W
A1 Jones, Bryn
A1 Ng, Rui Lun
A1 Alafaci, Annette
A1 Stub, Dion
A1 Lew, Philip
A1 Taylor, Andrew
YR 2024
UL http://medrxiv.org/content/early/2024/03/22/2024.03.20.24304640.abstract
AB Background Myocarditis is a rare but potentially serious complication of COVID-19 vaccination. Cardiac magnetic resonance (CMR) late gadolinium enhancement (LGE) imaging can identify cardiac scar, which may improve diagnostic accuracy and prognostication.Objectives To define the incidence of long-term LGE post COVID-19 vaccine-associated myocarditis (C-VAM) and to establish the additive role of CMR in the diagnostic work-up.Methods Patients with Brighton Collaboration Criteria Level 1 (definite) or Level 2 (probable) C-VAM were prospectively recruited from the Surveillance of Adverse Events Following Vaccination In the Community (SAEFVIC) database to undergo CMR at least 12 months after diagnosis. As there were limited patients with access to baseline CMR, prior CMR results were not included in the initial case definition. The presence of LGE on follow-up CMR was then integrated into the diagnostic algorithm and the reclassification rate (definite vs. probable) was calculated.Results Sixty-seven patients with C-VAM (mean age 30 ± 13 years, 72% male) underwent CMR evaluation. Median time from vaccination to CMR was 548 (range 398-603) days. Twenty patients (30%) had persistent LGE, most frequently found in the basal inferolateral segment (n = 11). At diagnosis, nine patients (13%) were classified as definite and 58 (87%) as probable myocarditis. With integration of CMR LGE data, 16 patients (28%) were reclassified from probable to definite myocarditis.Conclusion Persistent LGE on CMR occurs in one third of patients with C-VAM. Without CMR at diagnosis, almost one third of patients are misclassified as probable rather than definite myocarditis.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The ethics committees of the Royal Children's Hospital and Alfred Hospital name gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData available on reasonable request.AbbreviationsCMRCardiac Magnetic Resonance ImagingCOVID-19Coronavirus disease of 2019C-VAMCOVID-19 vaccine-associated myocarditisLGELate gadolinium enhancementMRIMagnetic Resonance ImagingTTETransthoracic echocardiographySAEFVICSurveillance of Adverse Events Following Vaccination In the Community